Method for reducing the likelihood of developing bladder or colorectal cancer in an individual human being
US11026982B2 · kind B2 · utility
Inventor
Key dates
| Filing date | Sep 22, 2020 |
| Grant date | Jun 8, 2021 |
| Priority date | — |
| Expiry date | Sep 22, 2040 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2035/11
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A method for treating an individual suffering from one of bladder cancer and colorectal cancer employs a CRISPR system to selectively kill or reduce the numbers of pathogenic bacteria within the individual and the individual is then administered an immune checkpoint inhibitor. In particular embodiments, the pathogenic bacteria is one of E. coli, Pseudomonas aeruginosa and Klebsiella bacteria, and the checkpoint inhibitor is selected from the group consisting of nivolumab, pembrolizumab, pidilizumab, AMP-224, AMP-514, STI-A1110, TSR-042, RG-7446, BMS-936559, MEDI-4736, MSB-0020718C, AUR-012 and STI-A1010. Further embodiments include enhancing the growth of a second bacteria in the individual, such bacteria including Akkermansia, Bacteroides, Bifidobacterium, Clostridium, Enterococcus, Fusobacterium, Lactobacillus, Propionibacterium, Ruminococcus, Veillonella, Prevotella, Escherichia and Streptococcus. Still other embodiments include increasing the levels of Roseburia and/or Faecalibacterium prausnitzii, in the individual's gut microbiome.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.